Scientific Opinion on the substantiation of health claims related to konjac mannan (glucomannan) and reduction of body weight (ID 854, 1556, 3725), reduction of post-prandial glycaemic responses (ID 1559), maintenance of normal blood glucose concentrations (ID 835, 3724), maintenance of normal (fasting) blood concentrations of triglycerides (ID 3217), maintenance of normal blood cholesterol concentrations (ID 3100, 3217), maintenance of normal bowel function (ID 834, 1557, 3901) and decreasing potentially pathogenic gastro-intestinal microorganisms (ID 1558) pursuant to Article 13(1) of Regulation (EC) No 1924/2006
Published:
Adopted:
Updated:
Wiley Online Library
Full article:
Meta data
Keywords
konjac mannan, glucomannan, glycaemic control, weight management, body weight, blood lipids, blood glucose, bowel function, intestinal transit, potentially pathogenic organisms, health claims
On request from
European Commission
Question Number
EFSA-Q-2008-1622
EFSA-Q-2008-1641
EFSA-Q-2008-2293
EFSA-Q-2008-2296
EFSA-Q-2008-3832
EFSA-Q-2008-3949
EFSA-Q-2008-4446
EFSA-Q-2008-4447
EFSA-Q-2008-1621
EFSA-Q-2008-2294
EFSA-Q-2008-2295
EFSA-Q-2008-4617
Panel members at the time of adoption
Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Hannu Korhonen, Pagona Lagiou, Martinus Løvik, Rosangela Marchelli, Ambroise Martin, Bevan Moseley, Monika Neuhäuser-Berthold, Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, Sean (J.J.) Strain, Stephan Strobel, Inge Tetens, Daniel Tomé, Hendrik van Loveren and Hans Verhagen.
Contact
Abstract
No abstract available
© European Food Safety Authority, 2010